ROLVEDON Biologic Drug Snags FDA Patent Extension
Published Date: 6/16/2025
Notice
Summary
The FDA has officially set the review period for ROLVEDON, a medicine that helps people, so its patent can be extended. This means the company behind ROLVEDON gets more time to protect their invention and keep making money before others can copy it. If you’re in the business of making or selling medicines, this update affects when new versions can enter the market.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
ROLVEDON Patent Extension Determined
The FDA has determined the regulatory review period for ROLVEDON to support an application to the U.S. Patent and Trademark Office for a patent extension on this human biological product. This lets the patent holder seek more time to protect the invention and continue exclusive sales before others can copy it.
Competition Delay for ROLVEDON
The FDA notice affects companies that make or sell medicines because setting the regulatory review period is part of the process that can delay when new versions or competitors may enter the market for ROLVEDON. If you are in the business of making or selling medicines, this update changes the timing of potential market entry for competing products.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in